LAVA Medtech Acquisition Corp.
Cash in trust
$119M
$119,299,973
Trust per share
$10.59
Redemption value
IPO
Oct 2021
$113M raised
Combination deadline
—
Not disclosed
Filings on record
48
Latest Feb 9, 2024
Overview
LAVA Medtech Acquisition Corp. is a special purpose acquisition company incorporated in Delaware and registered with the SEC under CIK 0001855450. It completed its initial public offering in Oct 2021, raising $113M in gross proceeds. The vehicle is sponsored by LAVA Medtech through LAVA Medtech Sponsor LP. The mandate targets healthcare, media & entertainment. Deadline lapsed without a deal; trust returned to public shareholders.
“we intend to focus our investment efforts on 1 TABLE OF CONTENTS industries that complement our management team’s background within healthcare and healthcare-related industries, primarily in the United States and Canada.”
Reading the filings
Arithmetic on what LAVA Medtech Acquisition Corp. has disclosed, written the way a desk would read it. These are observations, not a rating. Nothing here scores the vehicle or implies a view on it.
Trust versus the $10 unit
The trust holds $10.59 per public share, 5.9% above the $10.00 the units were sold at. That spread is accrued interest on the trust and, where the charter provides for it, sponsor contributions paid in to buy more time. It is the floor a public shareholder can redeem at, not a valuation of the business.
Extension history
Shareholders have already approved 1 extension. Each one opened a redemption window, so the public float and the trust are almost certainly smaller than at IPO, and each typically came with a sponsor contribution that lifts trust per share. A vehicle on its second or third extension is one where the sponsor is paying to keep the search alive.
Warrant coverage
Each unit carried one-half warrant per unit. Warrants are dilution deferred: they cost the holder nothing until exercised, and they overhang the post-combination share count. Thinner coverage is generally a sign of a stronger book at pricing.
Underwriting
RBC Capital Markets led the offering. It has been named on 19 SPAC IPOs, book-running 11 of them, and 63.2% of its resolved vehicles closed a deal. The syndicate has no control over whether a sponsor finds a target, but the quality of the book at pricing shapes who ends up holding the units.
Filings per month since the first one. A vehicle that has gone quiet with a deadline ahead is a different proposition from one that is still working.
48 filings in all. 2 in the last three months, against a busiest month of 18.
News on LAVA Medtech Acquisition Corp.
Last 90 daysNothing in the last 90 days that names this vehicle. We attribute a story only when the release carries the ticker or the registered name, so an empty section means no press release or wire story matched — not that nothing was published. The filings below are the primary record either way.
SEC filing history
Free tier: filings older than 24 hours- SC 13G/A
FORM SC 13G/A
Accession 0001062993-24-002620
- SC 13G/A
Amended beneficial ownership report (passive)
Accession 0001214659-24-000559
- 15-12G
Deregistration of securities
Accession 0001213900-23-039947
- 25-NSE
Notification of delisting
Accession 0001354457-23-000349
- 8-K
Other events
Item 8.01 · Accession 0001213900-23-038048
- 8-K
Submission of matters to a vote of security holders; Other events
Items 5.07, 8.01, 9.01 · Accession 0001213900-23-034639
- 8-K
Other events
Item 8.01 · Accession 0001213900-23-030749
- DEF 14A
Definitive proxy statement
Accession 0001104659-23-043676
- 10-K
Annual report
Accession 0001213900-23-024205
- PRE 14A
PRE 14A
Accession 0001104659-23-037199
- SC 13G
Beneficial ownership report (passive)
Accession 0001766806-23-000018
- SC 13G
Beneficial ownership report (passive)
Accession 0001193125-23-035768
- SC 13G/A
Amended beneficial ownership report (passive)
Accession 0001214659-23-002109
- 10-Q
Quarterly report
Accession 0001213900-22-072160
- 10-Q
Quarterly report
Accession 0001213900-22-048028
- 10-Q
Quarterly report
Accession 0001213900-22-027078
- SC 13G
Beneficial ownership report (passive)
Accession 0001062993-22-012345
- 10-K
Annual report
Accession 0001213900-22-018211
- NT 10-K
Late annual report notification
Accession 0001213900-22-017106
- SC 13G
Beneficial ownership report (passive)
Accession 0001213900-22-007546
- SC 13G
Beneficial ownership report (passive)
Accession 0001214659-22-002403
- SC 13G/A
Amended beneficial ownership report (passive)
Accession 0000935836-22-000089
- SC 13G
Beneficial ownership report (passive)
Accession 0001062993-22-003231
- 8-K
Other events
Items 8.01, 9.01 · Accession 0001104659-21-150449
- 10-Q
Quarterly report
Accession 0001104659-21-148683
- SC 13G
Beneficial ownership report (passive)
Accession 0000935836-21-000608
- 8-K
Other events
Items 3.02, 8.01, 9.01 · Accession 0001104659-21-134509
- 8-K
Entry into a material definitive agreement; Other events
Items 1.01, 3.02, 5.02, 5.03, 8.01, 9.01 · Accession 0001104659-21-132261
- 424B4
Final IPO prospectus
Accession 0001104659-21-130896
- EFFECT
Notice of effectiveness
Accession 9999999995-21-004038
Pro
Track LAVA Medtech Acquisition Corp. without the delay
Free accounts see this filing history a day late. Pro shows every document minutes after EDGAR publishes it, opens it on EDGAR in one click, and adds the twelve-month deadline calendar.
- Filings live, no 24-hour delay
- One click through to the source document
- Deadline calendar out to 12 months
- CSV export, API and MCP access
Cancel any time. Billed monthly in USD.
LAVA Medtech Acquisition Corp.: questions answered
What is LAVA Medtech Acquisition Corp.?
LAVA Medtech Acquisition Corp. is a special purpose acquisition company incorporated in Delaware and registered with the SEC under CIK 0001855450. It completed its initial public offering in Oct 2021, raising $113M in gross proceeds. The vehicle is sponsored by LAVA Medtech through LAVA Medtech Sponsor LP. The mandate targets healthcare, media & entertainment. Deadline lapsed without a deal; trust returned to public shareholders.
How much does LAVA Medtech Acquisition Corp. hold in trust?
Approximately $119,299,973, or about $10.59 per public share, as at the most recent filing on record. Trust balances move: shareholders redeem at extension votes and at the combination vote, and sponsors pay contributions in to extend. Treat the figure as a point-in-time disclosure, not a running balance.
When must LAVA Medtech Acquisition Corp. complete a merger?
No combination deadline appears in the filings we have indexed. The date is stated in the charter and repeated in each quarterly report; where our parser could not establish it with confidence we leave it blank rather than infer one.
What happens if LAVA Medtech Acquisition Corp. does not find a target in time?
The charter requires the vehicle to redeem 100% of the public shares and return the trust, pro rata, to public shareholders. That is the mechanism working as designed rather than a default. Founder shares and warrants are worthless in that outcome, which is why the sponsor's incentive is to get a deal done or to buy more time. Across the market, deadline lapsed without a deal; trust returned to public shareholders.
Can I redeem shares in LAVA Medtech Acquisition Corp., and at what price?
Public shareholders may elect to redeem in connection with a combination vote and at each extension vote, at the pro-rata trust value on the relevant record date, most recently disclosed at about $10.59 per share. Redemption is a right attached to the public shares only; warrants and rights carry no claim on the trust. The mechanics and the deadline for electing are set out in the proxy statement for the vote in question.
Is the trust value the same as the share price for LAVA Medtech Acquisition Corp.?
No. Trust per share is a disclosed, contractual figure: what a redeeming holder receives. The market price is whatever the shares change hands at, which can sit above the trust when a deal is well received or below it when the market doubts one will close. We do not have a current quote for this vehicle, so no spread is shown.
How much dilution do LAVA Medtech Acquisition Corp.'s founder shares and warrants create?
Each unit also carried one-half warrant per unit, which is dilution deferred until exercise. Both are disclosed in the prospectus and both survive into the combined company, which is why a de-SPAC at $10 is not economically the same as an IPO at $10.
Who sponsors LAVA Medtech Acquisition Corp., and what is their track record?
LAVA Medtech Sponsor LP is the sponsor entity, part of the LAVA Medtech franchise. This is the only vehicle we have attributed to that sponsor.
Which banks underwrote the LAVA Medtech Acquisition Corp. IPO?
RBC Capital Markets. RBC Capital Markets was credited as book-running manager on the cover. Syndicate membership and role are read from the prospectus cover and the underwriting section.
Is LAVA Medtech Acquisition Corp. a good investment?
That is not a question this site answers. LAVA Medtech Acquisition Corp. is covered here as reference data: what the company filed, when it filed it, and what the numbers in those filings say. The Edge, FOMO and Potential scores on this page are derived measures with a published formula, not ratings of investment merit: they describe the setup, and every component is shown so you can take them apart. We publish no price targets and no recommendations, and nothing here should be read as advice. The figures are a starting point for your own work, and each one carries the accession number of the filing it came from.
Where does this LAVA Medtech Acquisition Corp. data come from?
Filings LAVA Medtech Acquisition Corp. submitted to the SEC under CIK 0001855450: the registration statement and final prospectus for the structure, quarterly and annual reports for the trust, current reports and proxy statements for deals, votes and extensions. Trust economics are taken from the registrant's own XBRL tags rather than parsed from prose, which is why they are exact. Every filing in the history above is listed with its accession number, which identifies the document uniquely on EDGAR; Pro accounts open it directly from the row.
Compiled by the SPACListing research desk
Last reconciled Oct 19, 2026
Every figure on this page is read from documents the registrants filed with the U.S. Securities and Exchange Commission, principally the IPO prospectus (Form 424B4), quarterly and annual reports, current reports and proxy statements, the registrant's own XBRL tags for trust economics. Nothing is sourced from press coverage, from the companies themselves, or from a third-party aggregator. Where a filing does not disclose something, the field is left blank rather than estimated.
Read the full methodology · What is in the dataset · Report a correction
SPACListing is a reference-data service, not an investment adviser. Nothing here is a recommendation to buy or sell any security.
Continue reading
The context around this vehicle: who else the sponsor has launched, which banks priced it, and where it sits in the wider market.
LAVA Medtech: the full record
Every vehicle this sponsor has launched, what closed, what liquidated and what is still live.
RBC Capital Markets in SPACs
Mandates, bookrun credit, deal volume and the outcome of the vehicles it priced.
Healthcare SPACs
Every vehicle chasing the same mandate, ranked by cash in trust.
All liquidated spacs
Deadline lapsed without a deal; trust returned to public shareholders.
Deadline calendar
Which sponsors are running out of time, and when the extension votes land.
What is a SPAC?
The structure, the economics and where the risks actually sit.
SPAC glossary
Every term in a blank-check filing, defined the way practitioners use it.
How this data is built
Coverage universe, ingestion, normalisation, lifecycle classification and known limits.